Jefferies Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $23

6/27/24 11:37:35 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Jefferies analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $19 to $23.

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TEVA

Date	Price Target	Rating	Analyst
6/6/2025	$24.00	Buy	Goldman
5/28/2025	$25.00	Buy	Truist
5/12/2025	$23.00	Neutral → Overweight	Analyst
7/10/2024	$20.00	Hold → Buy	Argus
3/8/2024	$14.00	Underweight → Neutral	JP Morgan
2/12/2024	$12.00 → $19.00	Neutral → Overweight	Piper Sandler
1/23/2024	$10.00 → $14.00	Hold → Buy	Jefferies
1/3/2024	$8.00 → $12.00	Underweight → Neutral	Piper Sandler